441 related articles for article (PubMed ID: 33385331)
1. Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.
Bagati A; Kumar S; Jiang P; Pyrdol J; Zou AE; Godicelj A; Mathewson ND; Cartwright ANR; Cejas P; Brown M; Giobbie-Hurder A; Dillon D; Agudo J; Mittendorf EA; Liu XS; Wucherpfennig KW
Cancer Cell; 2021 Jan; 39(1):54-67.e9. PubMed ID: 33385331
[TBL] [Abstract][Full Text] [Related]
2. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.
Reader CS; Vallath S; Steele CW; Haider S; Brentnall A; Desai A; Moore KM; Jamieson NB; Chang D; Bailey P; Scarpa A; Lawlor R; Chelala C; Keyse SM; Biankin A; Morton JP; Evans TJ; Barry ST; Sansom OJ; Kocher HM; Marshall JF
J Pathol; 2019 Nov; 249(3):332-342. PubMed ID: 31259422
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
4. Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.
Lu H; Bowler N; Harshyne LA; Craig Hooper D; Krishn SR; Kurtoglu S; Fedele C; Liu Q; Tang HY; Kossenkov AV; Kelly WK; Wang K; Kean RB; Weinreb PH; Yu L; Dutta A; Fortina P; Ertel A; Stanczak M; Forsberg F; Gabrilovich DI; Speicher DW; Altieri DC; Languino LR
Matrix Biol; 2018 Sep; 70():20-35. PubMed ID: 29530483
[TBL] [Abstract][Full Text] [Related]
5. Influenza promotes collagen deposition via αvβ6 integrin-mediated transforming growth factor β activation.
Jolly L; Stavrou A; Vanderstoken G; Meliopoulos VA; Habgood A; Tatler AL; Porte J; Knox A; Weinreb P; Violette S; Hussell T; Kolb M; Stampfli MR; Schultz-Cherry S; Jenkins G
J Biol Chem; 2014 Dec; 289(51):35246-63. PubMed ID: 25339175
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
7. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
[TBL] [Abstract][Full Text] [Related]
8. Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis.
Tatler AL; Goodwin AT; Gbolahan O; Saini G; Porte J; John AE; Clifford RL; Violette SM; Weinreb PH; Parfrey H; Wolters PJ; Gauldie J; Kolb M; Jenkins G
PLoS One; 2016; 11(8):e0158047. PubMed ID: 27494713
[TBL] [Abstract][Full Text] [Related]
9. The roles of integrin αvβ6 in cancer.
Niu J; Li Z
Cancer Lett; 2017 Sep; 403():128-137. PubMed ID: 28634043
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
11. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
12. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
13. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence.
Allen MD; Thomas GJ; Clark S; Dawoud MM; Vallath S; Payne SJ; Gomm JJ; Dreger SA; Dickinson S; Edwards DR; Pennington CJ; Sestak I; Cuzick J; Marshall JF; Hart IR; Jones JL
Clin Cancer Res; 2014 Jan; 20(2):344-57. PubMed ID: 24150233
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs.
Pan F; Liu J; Chen Y; Zhu B; Chen W; Yang Y; Zhu C; Zhao H; Liu X; Xu Y; Xu X; Huo L; Xie L; Wang R; Gu J; Huang G
Sci Rep; 2024 Jun; 14(1):14248. PubMed ID: 38902343
[TBL] [Abstract][Full Text] [Related]
15. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Whilding LM; Parente-Pereira AC; Zabinski T; Davies DM; Petrovic RMG; Kao YV; Saxena SA; Romain A; Costa-Guerra JA; Violette S; Itamochi H; Ghaem-Maghami S; Vallath S; Marshall JF; Maher J
Mol Ther; 2017 Jan; 25(1):259-273. PubMed ID: 28129120
[TBL] [Abstract][Full Text] [Related]
16. E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling.
Eberlein C; Rooney C; Ross SJ; Farren M; Weir HM; Barry ST
Oncogene; 2015 Feb; 34(6):704-16. PubMed ID: 24488011
[TBL] [Abstract][Full Text] [Related]
17. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression.
Zhang J; Liang Q; Lei Y; Yao M; Li L; Gao X; Feng J; Zhang Y; Gao H; Liu DX; Lu J; Huang B
Cancer Res; 2012 Sep; 72(17):4597-608. PubMed ID: 22787120
[TBL] [Abstract][Full Text] [Related]
18. Regression of Triple-Negative Breast Cancer in a Patient-Derived Xenograft Mouse Model by Monoclonal Antibodies against IL-12 p40 Monomer.
Kundu M; Raha S; Roy A; Pahan K
Cells; 2022 Jan; 11(2):. PubMed ID: 35053375
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
20. A TGF-β-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis.
Li L; Liu J; Xue H; Li C; Liu Q; Zhou Y; Wang T; Wang H; Qian H; Wen T
Oncogene; 2020 Mar; 39(10):2125-2139. PubMed ID: 31811272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
